I
ntimal hyperplasia is a universal response of the arterial wall to mechanical injury, and it is a major cause of restenosis after percutaneous coronary interventions (PCIs). The multifactorial pathophysiology of restenosis remains as yet not entirely defined. Emerging experimental and clinical data indicate that inflammation is of major importance to the restenotic process.
Inflammatory cells are activated promptly after vascular injury 1 and recruited to the site of injury. [2] [3] [4] [5] These cells are capable of releasing mediators that facilitate smooth muscle cell (SMC) migration and proliferation. 6 -8 In human studies, the severity of postangioplasty luminal loss has been found to correlate with activation of circulating leukocytes, 9 and restenosis in patients undergoing directional atherectomy has been determined to be correlated with the percentage of macrophages in retrieved tissue at the time of angioplasty. 10 Recently, polymorphism of the gene for interleukin (IL)-1 receptor antagonist, a protein that regulates inflammatory response, was found to be associated with reduced restenosis. 11 Several antiinflammatory strategies have successfully limited neointimal hyperplasia after injury in animal models. Deactivation of circulating monocytes by IL-10 12 and blocking leukocyte adhesion by use of an antibody (Ab) directed against the ␤ 2 -integrin Mac-1 (CD11b/CD18) 13 reduce neointimal formation after balloon injury and/or stent deployment in rabbits. Furthermore, vascular injury in Mac-1-deficient mice is associated with reduced leukocyte accumulation and reduced neointimal formation. 14 The fundamental questions that arise are whether the stimulation of inflammation in vascular repair is specific or general and whether inflammation is localized to and controlled only at the site of injury alone or is responsive to systemic modulation. If injury is mediated by a specific inflammatory signal, then this specific pathway needs to be fully delineated and then targeted. Similarly, if the inflammatory process is local, then local therapy alone may suffice, whereas systemic inflammation might require systemic therapy. Finally, a systemic nonspecific response would be sensitive to preexisting inflammation and other inflammatory events, whereas specific localized effects would not. The present study was designed to examine these issues. Rabbits subjected to iliac artery balloon injury, with or without stent deployment, were assigned to bacterial lipopolysaccharide (LPS) injection immediately before and 1 day after the procedure. We report that activation of the innate immune system by LPS is associated with an increased neointimal formation and luminal loss after vascular injury. Furthermore, this augmentation of neointimal growth is blocked by administration of a monoclonal Ab (mAb) directed against CD14.
Methods

Vascular Injury Model
Animal care and procedures were in accordance with the guidelines of the American Association for the Accreditation of Laboratory Animal Care and the National Institutes of Health. Male New Zealand White rabbits (Covance Products, Denver, Pa), 2.8 to 3.2 kg, were fed rabbit chow and water ad libitum. Under anesthesia with xylazine (5 mg/kg IM) and ketamine (35 mg/kg IM), the femoral arteries were exposed and ligated, and the iliac arteries were denuded of endothelium by the intraluminal passage of a 3F arterial embolectomy catheter (Baxter) passed to the abdominal aorta and withdrawn in the inflated state 3 times. In 10 animals, a 9-mm metallic stent (NIR 7 cell, Medinol) mounted on a 3ϫ15-mm-long balloon was implanted in the right iliac artery (15-second inflation at 8 atm) immediately after denudation, resulting in marked arterial overstretch (stent-to-artery ratio 1.1:1 to 1.2:1). Heparin (100 U/kg IV) was administered immediately after arteriotomy, and animals were treated with aspirin (0.07 mg/mL in drinking water). LPS (Escherichia coli 0127:B8, Sigma) was injected (500 ng/rabbit IV) immediately before and 24 hours after injury. Arterial blood was collected into citrate-containing tubes at the time of the procedure and from the ear artery at 6 and 24 hours later. CD14 receptor blockade was performed by use of anti-rabbit CD14 mAb (generous gift of Dr R. Ulevich, La Jolla, Calif) 15 injected (2.5 mg/kg IV) at days Ϫ1 and ϩ5. Control animals were injected with murine IgG2a. Blockade of CD14 receptors was confirmed by flow cytometry analysis for CD14-positive blood monocytes.
Hemodynamics
The left common carotid artery was cannulated with a polyethylene catheter for blood pressure measurement (Gould Inc). Systemic blood pressure, heart rate, and respiratory rate were recorded under baseline conditions every minute for 30 minutes after LPS injection and at 30-minute intervals up to 8 hours.
Arterial Harvest and Analysis
Rabbits were euthanized by pentobarbital overdose. Iliac arteries were perfusion fixed with 10% neutral buffered formalin at physiological pressure. Balloon-injured arteries were embedded in paraffin, and 4 to 6 sections 5 m thick were cut from 3 equally spaced locations. Stented arteries were oriented longitudinally and embedded with a methacrylate formulation. Multiple 5-m-thick sections were cut with a tungsten carbide knife (Delaware Diamond Knives) on an automated microtome (Leica, Inc) from the proximal and distal ends and the midpoint of each stented segment. Measurements on Verhoeff's tissue elastin-stained sections were performed by use of Scion Image software (Scion Corp) running on a computer-assisted digital camera system (Sony Co) interfaced to a Nikon microscope. All sites were analyzed, and the results were averaged.
Immunohistochemistry
Species-specific antibodies were used to immunocytochemically identify macrophages (RAM 11, Dako Co). Rabbit spleen was used as a positive control; a nonspecific isotype Ab was used as a negative control. Standard immunocytochemical protocols were used in conjunction with heat-induced epitope retrieval. Deparaffinized and rehydrated sections were heated in a microwave for 20 minutes in 1ϫ Target Retrieval Solution (Dako), quenched with peroxidase, then incubated with the primary Ab (RAM-11 or nonspecific Ig) for 1 hour, followed by detection with the EnVisionϩ system (Dako). Sections were counterstained with Mayer's hematoxylin, then dehydrated and mounted. The RAM-11-positive cells, identified by brown staining, were divided by the total number of intimal and medial cells (3 sections for each slide).
Determination of Monocyte Activation
CD14 Expression on Monocytes
CD14 is a protein essential for LPS-induced cellular activation. CD14 expression is increased in the activated monocyte. The activation status of monocytes was examined in triplicate by fluorescence-activated cell sorting (FACS) with fluorescent anti-CD14 antibodies. Anticoagulated blood was incubated for 30 minutes (200 L, 4°C, in the dark) with mouse anti-human R-phycoerythrinconjugated anti-CD14 (4 L, Dako). FACS lysing solution (Becton Dickinson) was added for 15 minutes, and the residual cells were washed 3 times in FACS medium (PBS, 1% BSA, 0.02% sodium azide) (ϫ1500 rpm, 5 minutes, 4°C). Cells were then suspended in 1 mL of FACS medium, and flow cytometry was performed within 1 hour (Becton Dickinson flow cytometer). Monocytes were identified according to their forward-and side-scattering properties as well as fluorescence.
Serum IL-1␤ Determination
IL-1␤ is a major product of monocytes, secreted in response to LPS. Serum was separated and stored at Ϫ70°C until further analysis. After it was thawed, IL-1␤ levels were measured in triplicate with a commercial ELISA kit (Biosource International).
Statistical Analysis
All data are presented as meanϮSEM. Comparisons between treatment groups used an unpaired, 2-tailed t test. Values of PϽ0.05 were considered significant.
Results
Effect of LPS on Balloon Injury-Induced Intimal Hyperplasia
Morphometric analysis of balloon-injured arteries at 28 days after injury revealed concentric neointimal hyperplasia in both control and LPS-treated animals ( Figure 1, A-D) . Neointimal area was increased by 48% in LPS-treated rabbits. Neointima-to-media (N/M) ratio and luminal stenosis were increased significantly, by 91% and 65%, respectively (Figure 1E) . Luminal area was reduced by 29%. Total arterial area and medial area were reduced insignificantly in LPS-treated animals, by 12% and 20%, respectively. Arteries not injured by balloons revealed no histological difference between control and LPS-treated animals (data not shown). Administration of anti-CD14 Ab to balloon-injured animals did not affect neointimal growth. When it was administered to LPS-stimulated rabbits, the increase in neointimal growth was not significantly different from control levels ( Figure  1E ). Heart rate, blood pressure, and respiration were not changed significantly after injection of LPS.
Effect of LPS on Stent-Induced Intimal Hyperplasia
Not unexpectedly, intimal hyperplasia in control arteries implanted with NIR stents was relatively modest, with an intimal area of 0.57Ϯ0.07 mm 2 and stenosis of 9Ϯ1%. LPS treatment increased neointimal area significantly, by 35%, to 0.77Ϯ0.1 mm 2 and stenosis by 44%, to 13Ϯ1.7% (Figure 2 ; nϭ5, PϽ0.05 for both intimal area and stenosis). Medial area was unchanged and luminal area was reduced insignificantly by LPS (5.81Ϯ0.6 and 5.2Ϯ0.33 mm 2 , control and LPStreated, respectively).
Immunohistochemical Staining for Leukocytes
Macrophage infiltration into the injured arterial wall was recorded at 7 days after injury. LPS administration resulted in an increase in RAM11-positive cells in the vessel wall from 1.7Ϯ1.2% of total cells to 4.2Ϯ1.8% (Figure 3 ; nϭ4, PϽ0.05).
CD14 Expression on Blood Monocytes
CD14 expression on circulating monocytes was increased significantly in LPS-treated animals compared with injured controls. At 6 hours after vascular injury, there was a 120Ϯ25% increase in CD14 expression after LPS treatment, whereas no change was recorded in controls (nϭ4; Figure 4 ). Expression at 24 hours was increased by 64% and 30% in LPS-treated animals and controls, respectively. Anti-CD14 Ab administration was associated with complete disappear- Lower-and higher-magnification photomicrographs (Verhoeff staining) of arterial sections from control (A and B) and LPStreated (C and D) rabbits. Note thicker intima in LPS-treated rabbit. E, Bar graph showing increased intimal area, N/M ratio, and luminal cross-sectional area narrowing (% stenosis) in arteries of LPS-treated animals (nϭ6) vs control rabbits (nϭ8). Treatment with anti-CD14 blocked these LPS-induced effects but had no effect in control rabbits (nϭ4). *Pϭ0.05. ance of CD14-positive monocytes at 24 hours after injection (data not shown).
Serum IL-1␤
IL-1␤ levels in serum were increased at 6 hours after injury in both control and LPS-treated rabbits. At 24 hours after injury, IL-1␤ levels were increased by 79% over baseline levels in LPS-treated animals ( Figure 5A ) and reduced by 25% in controls (from 530Ϯ163 to 950Ϯ53 pg/mL and 474Ϯ273 to 352Ϯ162 pg/mL, LPS and control, respectively, meanϮSD; nϭ3 in each group; Pϭ0.016). To examine the predictive value of early nonspecific stimulation of the innate immune system on late intimal hyperplasia, the serum IL-1␤ change over baseline at 24 hours after injury was correlated with the N/M ratio at 30 days. A strong positive correlation was demonstrated (r 2 ϭ0.88), with the highest increase in IL-1␤ associated with the maximal N/M ratio ( Figure 5B ).
Discussion
Inflammation is essential to neointimal formation after experimental vascular injury and restenosis after percutaneous clinical vascular intervention. Leukocytes are central promoters and constituents of intimal proliferation, and vascular injury of many forms evokes a marked inflammatory state 1 that correlates with subsequent restenosis. 9 What has not been clear until now is whether the exacerbation of vascular injury by inflammation is a local phenomenon restricted to the site of injury alone or whether global and systemic inflammation, even of a nonspecific and preexisting nature, might contribute as well. It is as yet undefined whether systemic inflammatory mediators, such as C-reactive protein, that correlate with restenosis 16 are markers of increased risk or are causative in and of themselves. The present study demonstrates that LPS administration leads to increased neointimal growth, probably via systemic, nonspecific activation of leukocytes. Correlation was found between systemic inflammation, as measured by blood IL-1␤ levels, and late intimal growth.
Monocytes, macrophages, and neutrophils are immediately activated in response to infection and injury, 17 including vascular mechanical injury. 1 Neutrophils infiltrate an injured vessel wall rapidly, followed by monocytes. [3] [4] [5] Adaptive T lymphocyte-mediated immune responses are probably not involved in neointimal proliferation after balloon dilatation. 18 Thrombin-activated platelets and increased monocyte chemoattractant protein-1 expression by injured endothelial cells are among the stimuli that activate monocytes after vascular injury. Macrophages express numerous growth factors, cytokines, and enzymes that facilitate SMC migration and proliferation. 8 Systemic modulation of macrophage function inhibits neointimal formation by various modalities, including IL-10 deactivation of monocytes 12 and mAb blockade of Mac-1, a ␤ 2 -integrin expressed on leukocytes. 13 LPS administration stimulates blood monocytes, which increases production and secretion of growth factors. When administered with vascular balloon injury, LPS activated blood monocytes, increased systemic production of IL-1␤, and increased local vascular infiltration of macrophages, all associated with increased intimal hyperplasia. Even in an injury model in which the hyperplastic response is minimal, ie, after implantation of clinically available stents, LPS increased both inflammation and injury. Both systemic secretion of inflammatory mediators and/or increased arrival of highly activated monocytes to the site of injury may explain increased intimal growth. The early increase in serum IL-1␤ and its correlation with further intimal growth may indicate that systemic secretion is associated with the late growth effect, whereas the increased macrophage infiltration sup- ports a local effect. The 2 mechanisms, however, may be interrelated. The proinflammatory cytokine IL-1␤ increases adhesion of leukocytes to SMCs through increased expression of intercellular adhesion molecule-1 and CD 44 and increases IL-6 production by SMCs. Thus, IL-1␤ may indirectly affect SMC activation and proliferation and matrix formation, positively correlating with postinjury neointimal formation.
LPS affects cells involved in healing of vascular injury other than CD14-positive leukocytes. It can cause endothelial vacuolization and desquamation 19, 20 at much higher doses than those used in this study and increases intercellular adhesion molecule-1 expression on these cells. 21 LPS induces the expression of procoagulant tissue factor in epithelial cells 22 and activates vascular SMCs, 23 probably through soluble CD14 receptors. 23 In the present study, blockade of these receptors by mAbs abolished the enhanced formation of neointima after LPS. Thus, additional mechanisms other than the activation of CD14-positive monocytes may underlie the effect observed in this study. Interestingly, total blockade of CD14 in animals not treated with LPS had no effect on neointimal formation ( Figure 1E ). Thus, the inflammatory response that can affect vascular healing is secondary to several different stimuli, of which CD14-activation is but one.
Although "nonspecific" antiinflammatory drugs effectively reduce neointimal formation and restenosis after experimental vascular injury in a wide variety of models, their effects have not been reproduced in randomized clinical trials. The discrepancy and lack of clinical efficacy may result from inadequate dosing 24 ; from the increased inflammation associated with the surgery performed in animals before arteriotomy, unlike the "minimal" percutaneous procedure performed in humans; or from the large burden of inflammatory cells already present in human atherosclerotic lesions and the inability of the antiinflammatory regimen to block the acutephase innate response. In 2 clinical trials in which systemic glucocorticoids failed to affect restenosis, methylprednisolone was injected Ͻ24 hours before PCI with 25 or without 26 continuous steroid therapy. This mode of administration may initially stimulate macrophages, 27,28 and it may be that the rapid macrophage trafficking to the injured vessel 5 requires a more immediate and macrophage-specific systemic antiinflammatory protocol.
The association of a nonspecific inflammatory response and increased neointimal formation may have relevance for certain clinical situations associated with higher rates of adverse outcome, such as end-stage renal failure and dialysis, 29 both of which involve constant activation and phenotypic modulation of monocytes 30 that may affect their activity when recruited to the site of injury.
Systemic inflammation caused by infection, unrelated to the vascular injury, can modify the healing process. Cytomegalovirus infection increased neointimal formation after balloon injury, 31 probably via systemic inflammatory changes. 32 On the basis of the present study, we may assume that the inflammatory response that affects vascular healing is not pathogen specific.
Clinical or subclinical bacteremia may accompany up to 8% of PCIs. 33, 34 Although completely asymptomatic and subclinical, such bacteremia may stimulate the innate immune system, which in turn affects the long-term results of PCI. Thus, special caution regarding the prevention and detection of infection is warranted.
In conclusion, nonspecific systemic stimulation of the innate immune system concurrently with arterial injury is associated with increased neointimal formation, creating a cycle of injury and inflammation, which contribute to and stimulate each other. These findings add to our understanding of how the outcome of PCIs may differ, the lack of correlation between experimental and clinical studies, and how systemic inflammation should be considered and minimized whenever possible in the setting of intracoronary interventions.
